A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

a study on Lymphoma Non-Hodgkin Lymphoma

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
study ends around

Description

Summary

A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL

Official Title

A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Keywords

Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, B-Cell Lymphoma, TORL-5-700, TORL-5-700 at MTD/RP2D, TORL-5-700 at MTD/RP2D in combination with another agent, Monotherapy Expansion

Eligibility

You can join if…

Open to people ages 18 years and up

  • Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.
  • Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to
  • At least 1 measurable lesion per Lugano criteria.
  • Tumor tissue is available.
  • Adequate organ function

You CAN'T join if...

  • T-cell lymphoma
  • CLL or SL
  • Burkitt lymphoma and high-grade B-cell lymphoma
  • CNS involvement
  • Peripheral neuropathy > Grade 2
  • Uncontrolled medical conditions
  • Viral infections

Locations

  • UCLA accepting new patients
    Santa Monica California 90404 United States
  • Stanford University accepting new patients
    Stanford California 94305 United States
  • Sarah Cannon Research Institute accepting new patients
    Nashville Tennessee 37203 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
TORL Biotherapeutics, LLC
ID
NCT07439653
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 155 study participants
Last Updated
Contact us about this trial